Verastem's Pancreatic Cancer Drug Shows Strong 86% OS, 52% ORR in RAMP 205 Trial
VSTM is trading near its 52-week low of $3.55 (15% above the low).
Summary
Verastem announced highly positive updated results from its RAMP 205 trial for its combination therapy in first-line metastatic pancreatic cancer. The trial demonstrated an 86% six-month overall survival rate and a 52% objective response rate, with 83% of patients experiencing tumor shrinkage. This news follows a concurrent 8-K filing detailing these significant clinical data. These strong efficacy numbers for a notoriously difficult-to-treat cancer represent a major positive development and could substantially enhance the drug's commercial prospects. Nine patients are still on treatment, and the safety profile remained consistent.
At the time of this announcement, VSTM was trading at $4.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $352.4M. The 52-week trading range was $3.55 to $11.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.